Maprotiline: a review of its pharmacological properties and therapeutic efficacy in mental depressive states.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000374:Aggression / Q000187:drug effects; D000818:Animals; D000873:Anthracenes / Q000627:therapeutic use*; D000928:Antidepressive Agents; D001798:Blood Proteins / Q000378:metabolism; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D004347:Drug Interactions; D004569:Electroencephalography; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006993:Hypnotics and Sedatives; D066298:In Vitro Techniques; D007408:Intestinal Absorption; D007700:Kinetics; D007928:Lethal Dose 50; D008376:Maprotiline / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D008892:Milk / Q000378:metabolism; D009153:Mutagens; D011485:Protein Binding; D012098:Reproduction / Q000187:drug effects; D012119:Respiration / Q000187:drug effects
D000873:Anthracenes; D000928:Antidepressive Agents; D001798:Blood Proteins; D006993:Hypnotics and Sedatives; D009153:Mutagens; D008376:Maprotiline